Eli Lilly is the world's most valuable drugmaker, built on the back of GLP-1 shots Mounjaro and Zepbound.
Now it's spending billions to make sure that story doesn't end with one drug class.
The 4E Therapeutics Deal
Lilly acquired 4E Therapeutics, a startup developing non-opioid pain treatments that target the MNK-eIF4E signaling pathway in peripheral sensory neurons, for undisclosed terms.
Pain is a tough field, with a long history of failed trials, addiction risks, and regulatory headaches.
But the opioid crisis has left a massive opening for safer alternatives, pushing demand for non-addictive pain drugs higher every year.
That makes pain one of the last big areas of medicine where patients still rely on old drugs that don't work well, leaving a huge unmet market for whoever cracks it.
On its own, the 4E deal is small, but it fits a clear pattern - Lilly has rolled out acquisitions across pain, neuroscience, cancer, immunology, and heart and metabolism conditions, including last year's roughly $2.5 billion deal for cancer biotech Scorpion Therapeutics.
Every morning, Market Briefs breaks down deals like this in plain English - what they mean, who wins, and why they matter for your portfolio. Sign up and get a 45-minute investing masterclass as a bonus.
Why Lilly Is Buying Everything Not Named GLP-1
Five years ago, Lilly was worth less than $150 billion and pulling in under $25 billion in annual sales.
Today the stock is up more than 400%, putting Lilly ahead of every other pharma company by market cap.
That run came almost entirely from tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity.
But single-drug stories don't last forever - patents expire, competitors like Novo Nordisk push back, and new GLP-1 pills from rival drugmakers are working their way through late-stage trials.
So Lilly is plowing today's cash into tomorrow's pipeline, with more than $16.8 billion in operating cash flow generated in 2025.
Management has set a target of $120 billion in annual revenue by 2030 - nearly double 2025's roughly $65 billion - which means most of the growth has to come from outside weight loss.
The buildout isn't just acquisitions - Lilly has also committed more than $50 billion to new US manufacturing plants, betting on demand for today's GLP-1 supply and whatever comes next.
Some of those non-GLP-1 bets are already paying off, with Lilly's Alzheimer's drug Kisunla becoming one of the first treatments to slow the disease after its 2024 approval.
What To Watch
Pharma M&A has a rough track record, with most early-stage drug assets never reaching market - and Lilly is buying a lot of them.
Those bets need to start paying off before tirzepatide's exclusivity fades later this decade and Lilly loses its biggest revenue engine.
In the near term, the clearest signal will come from how many of these acquired drugs actually reach approval over the next two to three years.
Want a read like this on the market every morning? Join 350,000+ investors reading Market Briefs - you'll also get a free investing masterclass when you sign up.
